Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences

Rhea-AI Summary

Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its participation in two upcoming healthcare conferences. The company's CEO, Jasbir S. Seehra, Ph.D., will present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 10:30 a.m. ET, and the 7th Annual Evercore HealthCONx Conference on December 4, 2024, at 3:00 p.m. ET. Both presentations will be in a fireside chat format, with archived replays available on the Keros website for 90 days after each event.

LEXINGTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare conferences:

Piper Sandler 36^th Annual Healthcare Conference

• Date and Time: Tuesday, December 3, 2024 at 10:30 a.m. Eastern time
• Link: https://event.webcasts.com/starthere.jsp?ei=1699705&tp_key=2752037800
• Format: Fireside Chat Presentation
  

7^th Annual Evercore HealthCONx Conference

• Date and Time: Wednesday, December 4, 2024 at 3:00 p.m. Eastern time
• Link: https://wsw.com/webcast/evercore44/kros/2395197
• Format: Fireside Chat Presentation
  

For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event.

About Keros Therapeutics, Inc.

Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. The Company is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros’ second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.

Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042

FAQ

When is Keros Therapeutics (KROS) presenting at the Piper Sandler Healthcare Conference in 2024?

Keros Therapeutics (KROS) will present at the Piper Sandler Healthcare Conference on Tuesday, December 3, 2024, at 10:30 a.m. Eastern time.

What type of presentations will Keros Therapeutics (KROS) give at the December 2024 healthcare conferences?

Keros Therapeutics (KROS) will give fireside chat presentations at both the Piper Sandler Healthcare Conference and the Evercore HealthCONx Conference.

How long will the Keros Therapeutics (KROS) conference presentation replays be available?

The archived replays of both presentations will be available on the Keros website for up to 90 days following each event.

What is the main focus of Keros Therapeutics (KROS) research and development?

Keros Therapeutics focuses on developing therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins.